Tag Archives: Ph.D.

University of Southampton developed new drug with the potential to reverse resistance to immunotherapy

A new drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukaemias and non-Hodgkin … Read the full press release

Sandoz announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online … Read the full press release

Sanofi and subsidiary Genzyme announced that FDA approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS)

Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release

SAP shareholders approved the conversion of legal form to a European stock corporation (Societas Europaea, SE)

Annual General Meeting of Shareholders 2014 Mannheim, Germany,  21-5-2014 — /EuropaWire/ — The Annual General Meeting of Shareholders of SAP AG today approved all management proposals for the agenda items. With more than 99% of the votes, the shareholders approved the conversion … Read the full press release

The global leader in biosimilars Sandoz initiated Phase III clinical trial for biosimilar etanercept

Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global program underscores Sandoz’s leadership in biosimilars Holzkirchen, Germany, 1-7-2013 — /europawire.eu/ — Sandoz, the global … Read the full press release

MedImmune, NGM Biopharmaceuticals in exclusive agreement to discover, develop and commercialise therapies for diabetes and obesity

25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the … Read the full press release